Geulah Livshits
Stock Analyst at Chardan Capital
(0)
# 3916
Out of 5,240 analysts
182
Total ratings
25.32%
Success rate
-3.18%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Immuneering | Maintains: Buy | 13 13 | 1.96 | 563.27% | 9 | Jan 8, 2025 | |
Krystal Biotech | Maintains: Buy | 212 212 | 142.06 | 49.23% | 8 | Dec 18, 2024 | |
Tenaya Therapeutics | Maintains: Buy | 18 18 | 1.44 | 1150% | 9 | Dec 18, 2024 | |
Editas Medicine | Downgrades: Neutral | n/a | n/a | n/a | 10 | Dec 13, 2024 | |
CRISPR Therapeutics | Maintains: Buy | 94 94 | 38.34 | 145.17% | 11 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 10 12 | 3.81 | 214.96% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 15 | 2.77 | 441.52% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 62 62 | 10.45 | 493.3% | 14 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 88 91 | 9.68 | 840.08% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 7 | 0.59 | 1086.44% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 7 | 1.64 | 326.83% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 39 | 4.86 | 702.47% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 17 15 | 2.69 | 457.62% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 23 25 | 5.81 | 330.29% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 28 | 11.22 | 149.55% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 15 | 3.11 | 382.32% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 17 11 | 0.94 | 1070.21% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 6 | 1.16 | 417.24% | 5 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 29 34 | 5.89 | 477.25% | 10 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 41 41 | 5.79 | 608.12% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 25 | 5.99 | 317.36% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 2.21 | 442.99% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 30 25 | n/a | n/a | 4 | Mar 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 191 208 | 34.47 | 503.42% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 40 | n/a | n/a | 3 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 16 | 1.39 | 1051.08% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | 6.47 | -61.36% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 270 | n/a | n/a | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 90 | 7.03 | 1180.23% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 5.04 | -20.63% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 33 30 | 0.17 | 17547.06% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 30 | 4.36 | 588.07% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | 9.38 | 91.9% | 1 | Oct 27, 2020 |